In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinopharm Group Co. Ltd.

www.sinopharm.com

Latest From Sinopharm Group Co. Ltd.

'Buy China' In Procurement Schemes - Should You Worry?

A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.

China Commercial

Asia Deal Watch: Takeda, Eisai Team With Non-Profit On Review Of Novel Targets For Antibiotics

The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.

Asia Pacific Deals

Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses

Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.

Financing Hong Kong

China Investment Roundup: Active Deal-Making In Precision Medicine

Winter is coming, yet China’s financial market is still hot for healthcare companies looking at a prosperous period of investment before the year ends. Capital investments from Chinese investors dramatically increased in November, particularly in the precision medicines segment. Although Chinese Creat Group’s expected record-breaking outbound pharmaceutical acquisition deal worth $1.5bn failed to gain US approval, cross-border M&A remained active.

China Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register